<DOC>
	<DOCNO>NCT01953926</DOCNO>
	<brief_summary>This open-label , multicenter , multinational , Phase 2 study explore efficacy safety neratinib therapy patient solid tumor activate HER2 , HER3 EGFR mutation EGFR gene amplification .</brief_summary>
	<brief_title>An Open-label , Phase 2 Study Neratinib Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor ( EGFR , HER2 , HER3 ) Mutations EGFR Gene Amplification</brief_title>
	<detailed_description>This open-label , multicenter , multinational , Phase 2 study explore efficacy safety neratinib therapy patient solid tumor activate HER2 , HER3 EGFR mutation EGFR gene amplification . The trial consist screen period , treatment period , end treatment visit occur neratinib discontinue reason , safety follow-up visit occur 28 42 day last dose neratinib survival follow-up period last maximum 12 month patient last dose neratinib initiation additional anti -cancer therapy . Treatment consist neratinib alone 240 mg daily HER2 mutate cancer exclude hormone positive breast cancer bladder cancer , neratinib 240 mg daily paclitaxel 80 mg/m^2 IV Days 1 , 8 , 15 every 4 week cycle bladder cancer , neratinib 240 mg daily fulvestrant 500 mg Days 1 , 15 first month , Day 1 every 4 week cycle hormone positive breast cancer .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histologically confirm cancer curative therapy exists . Documented HER2 mutation . Prior treatment panHER TKI ( eg , lapatinib , afatinib , dacomitinib , neratinib ) . Patients receive anticancer agent . Symptomatic unstable brain metastasis . Women pregnant breastfeeding . Note : There additional inclusion exclusion criterion . The study center determine meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Neratinib</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Breast</keyword>
	<keyword>Gastroesophageal</keyword>
	<keyword>Endometrial Ovarian Cancer</keyword>
	<keyword>Biliary Tract</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>HER2</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Bladder/Urinary Tract</keyword>
</DOC>